The value proposition of molecular medicine
- PMID: 22376267
- PMCID: PMC5404828
- DOI: 10.1111/j.1752-8062.2011.00386.x
The value proposition of molecular medicine
References
-
- Honig PK. Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology. Clin Pharmacol Ther. 2011; 89: 151–156. - PubMed
-
- Terzic A, Waldman SA. Translational medicine: path to personalized and public health. Biomark Med. 2010; 4: 787–790. - PubMed
-
- Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science. Clin Pharmacol Ther. 2011; 90: 10–13. - PubMed
-
- Waldman SA, Terzic A. Patient‐centric clinical pharmacology advances the path to personalized medicine. Biomark Med. 2011; 5: 697–700. - PubMed
-
- Nelson TJ, Terzic A. Induced pluripotent stem cells: an emerging theranostics platform. Clin Pharmacol Ther. 2011; 89: 648–650. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
